ReGEN Biomedical
ReGEN Biomedical BV is a Maastricht-based private startup developing automated production platforms that manufacture functional micro-tissues and macro-tissues for pharmaceutical toxicity screening and regenerative medicine therapies, serving pharma, regenerative medicine developers, and academic research institutions as part of the RegMed XB Pilotfactory network.
- Company typePrivate
- Founded2021
- HeadquartersMaastricht, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ReGEN Biomedical does
ReGEN Biomedical BV is a Maastricht, Netherlands-based private startup (founded 2021, ~16 employees) that develops automated production platforms for manufacturing functional micro-tissues and macro-tissues used in regenerative medicine, drug toxicity screening, and ex vivo disease modeling. Its core technology spans microfluidic cell culture, stem cell differentiation (including iPSC lines), bioprinting, and bioreactor-based tissue assembly, with advanced offline and inline quality control designed to bridge the gap between manual laboratory workflows and industrial-scale, GMP-ready production. The company offers functional micro-tissues for pharma toxicity and screening applications, assembles micro-tissues into macro-tissues as building blocks for organ-mimicking constructs, and licenses or co-develops its automated manufacturing platforms with partners progressing from research toward clinical and commercial applications.
ReGEN operates as the manufacturing translation arm of the RegMed XB Pilotfactory network — a consortium of research institutions, governments, provinces, health funds, and businesses coordinating four pilot plants in Eindhoven, Leiden, Maastricht, and Utrecht — with €646 million of Dutch Nationaal Groeifonds funding allocated to the program. It additionally participates in the pan-European EHAB consortium spanning seven countries, and holds partnerships with Maastricht University, Maastricht UMC+, Brightlands, Demcon Scinus, NecstGen, and other regenerative medicine ecosystem players. Its customer base spans pharmaceutical companies, regenerative medicine therapy developers, academic research institutions, and downstream healthcare providers treating chronic diseases (type 1 diabetes, kidney failure, osteoarthritis, heart failure), though no named commercial customers are disclosed.
The business model blends product sales (micro-tissue products for screening), managed services and co-development agreements with pharma and regenerative medicine partners, and an open-innovation R&D funding program with structured calls (e.g., Scalable Expansion of Human Cells, TissueFlux) supporting its technology roadmap. Distribution is direct B2B enterprise sales targeting pharma, regenerative medicine developers, and research institutions. Pricing is not publicly disclosed and engagements are structured as custom enterprise collaborations, while the company remains at research scale with explicit intent to industrialize toward regulated commercial manufacturing.
ReGEN Biomedical firmographics
Firmographics- Name
- ReGEN Biomedical
- Legal name
- ReGEN Biomedical BV
- Website
- https://regenbiomedical.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ReGEN Biomedical BV is a Maastricht-based private startup developing automated production platforms that manufacture functional micro-tissues and macro-tissues for pharmaceutical toxicity screening and regenerative medicine therapies, serving pharma, regenerative medicine developers, and academic research institutions as part of the RegMed XB Pilotfactory network.
- Ownership category
- akta.pro rank
ReGEN Biomedical industry classification
Industry- Product category
- Regenerative Medicine Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where ReGEN Biomedical is headquartered
LocationHeadquarters
- HQ city
- Maastricht
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
ReGEN Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Micro-tissue Products: Sale of functional micro-tissues for toxicity and pharma screening applications to pharmaceutical companies and research institutions.
- Regenerative Medicine Manufacturing Services: Supporting partners as they progress from research toward clinical, commercial, or other regulated applications through development programs and manufacturing expertise.
- R&D Project Funding: ReGEN Biomedical offers targeted funding for high-impact R&D projects through development programs, supporting the development of scalable manufacturing equipment that aligns with their roadmap.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ReGEN Biomedical product offering
Product offeringCore offering
ReGEN Biomedical develops and manufactures functional micro-tissues and macro-tissues for use in pharmaceutical toxicity screening and regenerative medicine therapies, using proprietary automated production platforms with advanced quality control. The company supports partners transitioning from research toward clinical, commercial, or other regulated applications, and also operates R&D development programs targeting scalable human cell expansion and high-throughput tissue visualization technologies.
Product overview
ReGEN Biomedical is a regenerative medicine manufacturing company offering a portfolio centered on functional micro-tissues and macro-tissues for toxicity testing, pharmaceutical screening, and personalized medicine applications. The company operates at research scale while building automated production platforms equipped with advanced offline and inline quality control systems. Their product portfolio includes: (1) Functional Micro-Tissues as the core product for drug testing and regenerative therapies, (2) Macro-Tissues assembled from micro-tissues to mimic patient organs, (3) Automated Production Platforms for scalable manufacturing, and (4) R&D Development Funding Programs supporting scalable expansion of human cells and high-throughput tissue visualization technologies.
Differentiator
Problem solved
Functional benefit
Products and services
- Functional Micro-Tissues Robust and reproducible small pieces of tissue produced for pharmaceutical toxicity screening and as building blocks for regenerative medicine therapies. They serve as alternatives to animal testing and represent the next step in mimicking patient organs for personalized medicine.
- Macro-Tissues Functional pieces of human organs assembled from micro-tissues as building blocks, designed to mimic patient organs for personalized medicine applications and provide the foundation for regenerative medicine implants.
- Automated Production Platforms Scalable, automated manufacturing equipment that moves regenerative medicine production from manual, labor-intensive laboratory procedures to industrial-scale processes. Equipped with advanced offline and inline quality control and built to support partners progressing from research toward clinical, commercial, or other regulated applications.
- Ex Vivo Disease Models Disease models developed using functional micro-tissues that enable pharmaceutical drug screening and ex vivo testing, supporting research applications and reducing reliance on animal testing.
Companies that use ReGEN Biomedical
Customer profileSegments4 records
Ideal customer profiles3 records
ReGEN Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ReGEN Biomedical partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered flagship, core and minor.
- RegMed XBflagshipRegMed XB is the overarching consortium partnership of research institutions, governments, provinces, health funds and businesses in the Netherlands and Flanders. ReGEN Biomedical is part of the international RegMed XB Pilotfactory, which aims to develop therapies for chronic diseases based on stem cells, mini-organs, tissues and smart biomaterials. The RM factory consists of four pilot plants in Eindhoven, Leiden, Maastricht and Utrecht.
- Brightlands (Brightlands Maastricht Health Campus)coreBrightlands Maastricht Health Campus is a key ecosystem partner. ReGEN Biomedical is part of the Brightlands Biomedical Ecosystem, providing access to research infrastructure and collaborative networks in the health sciences sector.
- Maastricht UniversitycorePartner in the REACT-EU project to build a proof-of-concept assembly line for production platforms for automated and affordable production of cells and micro/macro tissue. UM has built up an impressive IP portfolio in regenerative medicine.
- Maastricht UMC+coreCollaborating partner in the REACT-EU Industriële RG Assemblagelijn project for developing production platforms for automated and affordable production of stem cells and micro/macro tissue.
- EHAB ConsortiumflagshipEuropean Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB) aims to strengthen the European landscape in Advanced Therapies and Biomaterials by building an interconnected value chain. ReGEN Biomedical is a participant via Brightlands.
- Flanders.BIOminorBelgian partner in the EHAB consortium, contributing to transregional AT&B value chain development.
- BioRegio STERNminorGerman partner in the EHAB consortium, contributing to strengthening European AT&B innovation ecosystems.
- A4TECminorPortuguese partner in the EHAB consortium, contributing to European regenerative medicine ecosystem development.
- BIOCATminorSpanish partner in the EHAB consortium, contributing to transregional AT&B value chain strengthening.
- Research Institutes of Sweden AB (RISE)minorSwedish partner in the EHAB consortium, contributing to European AT&B ecosystem development.
- MedSilesiaminorPolish partner in the EHAB consortium, contributing to European regenerative medicine ecosystem strengthening.
- Brabant Development Agency (BOM)minorDutch partner in the EHAB consortium, contributing to regional AT&B value chain development in North-Brabant.
- RegMed XB Consortium (Endorsing)coreEndorsing organization for EHAB, the RegMed XB consortium supports the joint action plan to strengthen innovation ecosystems at EU, national, regional, and local levels.
- Fraunhofer IPAminorGerman research institute (Fraunhofer-Institut für Produktionstechnik und Automatisierung) endorsing the EHAB consortium, bringing expertise in production technology and automation.
- NecstGenminorPartner logo displayed on website, contributing to regenerative medicine ecosystem.
- Clemens van BlitterswijkminorStrategic Advisory Board member from MERLN Institute, bringing expertise in regenerative medicine research and development.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
ReGEN Biomedical competitors and assessment
Company assessmentDirect peers
- Aspect Biosystems: Develops bioprinted tissue therapeutics and microfluidic 3D cell culture platforms. Comparable technology stack (microfluidics + bioprinting) and dual pharma/RM go-to-market focus.
- CELLINK (BICO): Global leader in bioprinting, 3D cell culture, and regenerative medicine laboratory automation. Directly comparable to ReGEN as both develop automated platforms enabling tissue engineering and drug-screening workflows for pharma and RM customers.
- Organovo: Pioneer in 3D bioprinted human tissues for drug discovery and therapeutic applications. Closely comparable to ReGEN's micro/macro-tissue production and pharma screening use cases.
- Poietis: French bioprinting company developing automated tissue manufacturing platforms for regenerative medicine and in vitro testing. Directly comparable in automated tissue manufacturing and European footprint.
- CN Bio: UK-based developer of organ-on-chip and microphysiological systems for drug discovery and disease modeling. Directly comparable as a provider of functional micro-tissue / organ-mimetic platforms for pharma toxicity screening.
- Cyfuse Biomedical: Japanese biotech commercializing a proprietary 3D bioprinting platform (Kenzan method) for regenerative medicine applications, including cell-based therapies. Comparable automated scaffold-free tissue manufacturing approach.
Broad incumbents
- Lonza Cell & Gene Technologies: Global CDMO leader in cell and gene therapy manufacturing. Comparable as a potential competitor and partner for GMP-scale regenerative medicine manufacturing services ReGEN aspires to provide.
- Catalent: Major CDMO with growing cell therapy and biologics manufacturing capabilities. Comparable as a large-scale alternative for partners seeking outsourced regenerative-medicine manufacturing.
- 3D Systems (Regenerative Medicine / Volumetric Biotechnologies): Through its regenerative medicine programs (historically via Volumetric), develops 3D-printed tissue and organ constructs. Comparable in bioprinted-tissue ambition and pharma drug-screening applications.
Emerging players
- RegenHU: Swiss manufacturer of bioprinters and 3D tissue fabrication systems. Comparable as an equipment-and-platform provider enabling tissue engineering and regenerative medicine research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ReGEN Biomedical social profiles
Digital presenceReGEN Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReGEN Biomedical leadership team
Management profileNumber of profiles
Profiles6 records
ReGEN Biomedical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReGEN Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReGEN Biomedical
What does ReGEN Biomedical do?
ReGEN Biomedical develops and manufactures functional micro-tissues and macro-tissues for use in pharmaceutical toxicity screening and regenerative medicine therapies, using proprietary automated production platforms with advanced quality control. The company supports partners transitioning from research toward clinical, commercial, or other regulated applications, and also operates R&D development programs targeting scalable human cell expansion and high-throughput tissue visualization technologies.
Is ReGEN Biomedical a public or private company?
ReGEN Biomedical is a private company. It is classified as unknown and is currently operating.
When was ReGEN Biomedical founded?
ReGEN Biomedical was founded in 2021. It employs 1 to 10 people.
Where is ReGEN Biomedical based?
ReGEN Biomedical is headquartered in Maastricht, Netherlands, in the Europe region.
How does ReGEN Biomedical make money?
Three revenue lines are on record. Micro-tissue Products are the primary driver. The others are regenerative Medicine Manufacturing Services and R&D Project Funding.
Who are ReGEN Biomedical's main competitors?
Direct peers on record are Aspect Biosystems, CELLINK (BICO), Organovo, Poietis, CN Bio and Cyfuse Biomedical. Broad incumbents are Lonza Cell & Gene Technologies, Catalent and 3D Systems (Regenerative Medicine / Volumetric Biotechnologies). RegenHU is listed as an emerging player.
Does ReGEN Biomedical have an API?
No public API is recorded for ReGEN Biomedical.
What industry is ReGEN Biomedical in?
ReGEN Biomedical's product category is Regenerative Medicine Manufacturing. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.